Featured Speakers

• 

  Jonny FinlayDirector, Protein Discovery and Optimization Pfizer

• 

  Ira PastanHead, Molecular Biology Section NCI, NIH

• 

  George GiorgiouProfessor University of Texas, Austin

• 

  Bill StrohlVice President, Biologics Research Johnson & Johnson

Develop Antibodies with Better Clinical and Commercial Potential

Understanding new discovery and engineering technologies and approaches being used by other drug developers is critical. Learning how to take them forward within your organization is priceless. 

That’s where this conference comes in.

Unlike other antibody conferences, Antibody Engineering and Discovery 2013 is a meeting that doesn’t just give you a comprehensive overview and in-depth understanding and of what other drug developers are doing…

It’s also a meeting that will noticeable change the way you operate on your return to the lab, by giving you the opportunity to uncover how to use the new approaches used by your competitors. All so that you can move your own antibody pipeline forward.

With a focus on delivering results in a commercial environment, this is a meeting that will help you:

• Adapt, or adopt new, discovery platforms to improve the therapeutic potential of your antibody candidates
• Enhance biophysical and functional properties to differentiate your antibody and enhance clinical performance
• Understand how drug developers are using novel antibody-based formats to meet their clinical and commercial goals 

Because delivering in a commercial environment is the focus, speakers and delegates are dominated by drug developers who can tell you first-hand how to discover and develop differentiated antibodies. Presenters include heads of antibody programs from Pfizer, Novartis, Merck, AbbVie, MedImmune, Amgen and BMS. 

Download the brochure

Heavyweights of the antibody field, George Georgiou and Ira Pastan, will outline radically different discovery and engineering approaches that will help propel your development efforts forwards. Plus, the FDA  will update you on their evolving regulatory expectations regarding antibody development.

Get more details of who is speaking and what’s being covered here.

Take Away Useable Information That Will Make a Difference to Your Business 

So how can you be sure attending this conference becomes the best two days you spend away from the lab this year?

This is a very different type of antibody meeting. You’ve said that the quality of discussion and the usability of the knowledge you take away from the meeting is critical. 

Download the brochure

The conference will deliver information that’ll make a tangible difference to your performance when you return. A premium is placed on knowledge sharing and networking. Here’s how:

• Restricting the number of attendees to 100. This promotes knowledge sharing and makes it possible to meet every speaker and delegate. This is an intimate meeting; you can have in-depth conversations that deliver solutions.
• The audience is weighted so that at least 70% of attendees are drug developers. You’ve said it’s critical that you learn from and meet other drug developers. The confirmed speakers are a great snapshot of the type of people who attend.
• A focus on overcoming commercial challenges. You can easily read the literature to understand what new discovery and engineering platforms are available. Attend this meeting to understand why and how new approaches are being adopted by drug developers.
• Innovative networking sessions built into the agenda: Speed Networking, Master Mind Groups, Interactive Panel Discussions. There are over ten hours of informal networking built into the agend
• Speakers are invited from referrals only. To ensure the speakers truly have something valuable to say, we only invite people who have been nominated by their peers. Speakers are selected for their pioneering work, innovative approaches and a willingness to challenge existing thinking.

View Agenda | Packages & Pricing | Register Now | Contact Us